Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance

dc.creatorSIMÕES, Belinda Pinto
dc.creatorBRAGA JUNIOR, José Wilson Ramos
dc.creatorREGO, Maria Aparecida do Carmo
dc.creatorSOUZA, Cármino Antônio de
dc.date2011
dc.date2013-09-18T13:20:18Z
dc.date2016-06-21T20:06:44Z
dc.date2013-09-18T13:20:18Z
dc.date2016-06-21T20:06:44Z
dc.date.accessioned2018-03-29T01:52:35Z
dc.date.available2018-03-29T01:52:35Z
dc.identifierRevista Brasileira de Hematologia e Hemoterapia, v.33, n.1, p.65-72, 2011
dc.identifier1516-8484
dc.identifier10.5581/1516-8484.20110017
dc.identifierhttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000100017
dc.identifierhttp://www.scielo.br/pdf/rbhh/v33n1/v33n1a17.pdf
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/1711
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/1711
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1308189
dc.descriptionImatinib mesylate was the first BCR-ABL-target agent approved for the treatment of chronic myeloid leukemia. Although most patients respond well to imatinib therapy, the literature shows that one third develops resistance or intolerance. The timing of second-line treatment after failure of initial treatment may have a significant impact on long-term outcome. Thus, appropriate monitoring to identify resistance and/or intolerance is crucial to early intervention with second generation tyrosine kinase inhibitors and attainment of better results
dc.description33
dc.description1
dc.description65
dc.description72
dc.languageeng
dc.publisherAssociação Brasileira de Hematologia e Hemoterapia e daSociedade Brasileira de Transplante de Medula Óssea
dc.publisherBrasil
dc.relationRevista Brasileira de Hematologia e Hemoterapia
dc.rightsaberto
dc.rightsCopyright Associação Brasileira de Hematologia e Hemoterapia e daSociedade Brasileira de Transplante de Medula Óssea
dc.sourceSciELO
dc.subjectLeukemia, myelogenous, chronic, BCR-ABL positive - drug therapy
dc.subjectDrug resistance
dc.subjectDrug monitoring, neoplasm
dc.subjectReceptor Protein-Tyrosine Kinases
dc.subjectPyrimidines - therapeutic use
dc.subjectAntineoplastic agents - administration & dosage
dc.subjectMonitoring
dc.subjectPrognosis
dc.titleImportance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance
dc.typeArtículos de revistas
dc.typeArtículos de revistas
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución